

118TH CONGRESS
1ST SESSION

H. R. 4011

To amend title XXVII of the Public Health Service Act to improve patient access to oral medications, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

JUNE 12, 2023

Mr. BILIRAKIS (for himself and Ms. SEWELL) introduced the following bill;
which was referred to the Committee on Energy and Commerce

A BILL

To amend title XXVII of the Public Health Service Act to improve patient access to oral medications, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Timely Access to Clin-
5 ical Treatment Act of 2023” or the “TACT Act of 2023”.

6 **SEC. 2. PATIENT ACCESS TO ORAL MEDICATIONS.**

7 (a) IN GENERAL.—Section 2719A of the Public
8 Health Service Act (42 U.S.C. 300gg–19a) is amended by
9 adding at the end the following new subsection:

10 “(f) ACCESS TO ORAL MEDICATIONS.—

1 “(1) REQUIREMENTS FOR CONTRACTS BE-
2 TWEEN GROUP HEALTH PLANS OR HEALTH INSUR-
3 ANCE ISSUERS AND PHARMACIES.—If a group health
4 plan or a health insurance issuer offering group or
5 individual health insurance coverage covers or pro-
6 vides any benefits for oral medications (as defined in
7 paragraph (4)) and enters into a contract with a
8 pharmacy, whether directly or through an agent of
9 such plan or issuer (including a pharmacy benefits
10 manager) to dispense such medications to partici-
11 pants, beneficiaries, or enrollees of the plan or cov-
12 erage, such plan or issuer shall require, as condi-
13 tions of such contract, such pharmacy to carry out
14 the procedures described in paragraph (2).

15 “(2) PROCEDURES DESCRIBED.—For purposes
16 of paragraph (1), the procedures described in this
17 paragraph with respect to a participant, beneficiary,
18 or enrollee of the plan or coverage and a health care
19 provider who submits to such pharmacy a prescrip-
20 tion for an oral medication for such participant, ben-
21 eficiary, or enrollee are the following (as applicable):

22 “(A) PHARMACY CONFIRMATION OF ABIL-
23 ITY TO DISPENSE.—Not later than 24 hours
24 after receiving such prescription—

1 “(i) confirm to such health care pro-
2 vider that such pharmacy received such
3 prescription; and

4 “(ii) inform such health care provider
5 as well as such plan or issuer whether such
6 pharmacy will dispense such oral medica-
7 tion to such participant, beneficiary, or en-
8 rollee by not later than 72 hours after re-
9 ceiving such prescription, including any
10 time for benefits verification, prior author-
11 ization, or any other administrative proce-
12 dure required by the agent of such plan or
13 issuer (including a pharmacy benefits man-
14 ager) prior to authorizing the pharmacy to
15 dispense the medication.

16 “(B) PHARMACY ABLE TO FILL PRESCRIP-
17 TION.—In the case that such pharmacy informs
18 such health care provider under subparagraph
19 (A)(ii) that such pharmacy is able to dispense
20 such oral medication to such participant, bene-
21 ficiary, or enrollee by the 72-hour deadline de-
22 scribed in such subparagraph, dispense such
23 oral medication to such participant, beneficiary,
24 or enrollee by such deadline.

“(C) PHARMACY UNABLE TO FILL PRESCRIPTION.—In the case that such pharmacy informs such health care provider under subparagraph (A)(ii) that such pharmacy is not able to dispense such oral medication to such participant, beneficiary, or enrollee by the 72-hour deadline described in such subparagraph, immediately provide a written notice to—

“(i) the prescribing physician or other health care provider;

“(ii) the group health plan or a health insurance issuer offering group or individual health insurance coverage; and

“(iii) such participant, beneficiary, or enrollee,

with a clear and understandable explanation of such inability and of the option of such participant, beneficiary, or enrollee to be dispensed such oral medication from any provider or pharmacy described in subparagraph (C) of paragraph (3), in accordance with the requirements described in subparagraphs (A) and (B) of such paragraph.

“(D) PHARMACY FAILURE TO COMMUNICATE.—If the pharmacy does not commu-

1 nicate its ability to dispense as required by sub-
2 paragraph (A), or, after confirming that it will
3 dispense an oral medication under such sub-
4 paragraph, does not actually dispense such
5 medication by the 72-hour deadline described in
6 such paragraph, such pharmacy shall be
7 deemed to have confirmed that it is not able to
8 dispense such medication under subparagraph
9 (C).

10 “(3) REQUIREMENTS FOR GROUP HEALTH
11 PLANS AND HEALTH INSURANCE ISSUERS.—

12 “(A) PATIENT SELECTION OF ALTERNATE
13 PROVIDER OR PHARMACY.—If a group health
14 plan or a health insurance issuer offering group
15 or individual health insurance coverage (or its
16 agent, including a pharmacy benefits manager)
17 described in paragraph (1) enters into a con-
18 tract described in such paragraph, with a phar-
19 macy and such pharmacy, with respect to a
20 participant, beneficiary, or enrollee of the plan
21 or coverage and a health care provider who sub-
22 mits to such pharmacy a prescription for an
23 oral medication for such participant, bene-
24 ficiary, or enrollee, informs such health care
25 provider under subparagraph (A)(ii) of such

1 paragraph that such pharmacy will not dispense
2 such oral medication to such participant, bene-
3 ficiary, or enrollee by the 72-hour deadline de-
4 scribed in such subparagraph (or in the case
5 that the participant, beneficiary, or enrollee has
6 not received the oral medication by the 72-hour
7 deadline), the plan or issuer—

8 “(i) shall authorize such participant,
9 beneficiary, or enrollee to select any pro-
10 vider or pharmacy described in subpara-
11 graph (C) to dispense such oral medication
12 to such participant, beneficiary, or enrollee
13 based on the written notice described in
14 paragraph (2)(C) or a certification by a
15 the prescribing physician or other health
16 professional that the participant, bene-
17 ficiary, or enrollee has not received the oral
18 medication by the 72-hour deadline; and

19 “(ii) in the case that the provider or
20 pharmacy selected under clause (i) does
21 not have a contract with such plan or
22 issuer to dispense such oral medication to
23 such participant, group health plan or a
24 health insurance issuer offering group or
25 individual health insurance coverage de-

scribed in paragraph (1) shall cover the medication and pay the provider or pharmacy in accordance with the provisions of subparagraph (B).

“(B) COVERAGE REQUIREMENTS FOR PRESCRIPTIONS DISPENSED BY ALTERNATE PROVIDER OR PHARMACY.—For prescriptions dispensed by an alternate provider or pharmacy in accordance with subparagraph (A) that does not have a contract with a group health plan or a health insurance issuer offering group or individual health insurance coverage (or its agent, including a pharmacy benefits manager) described in paragraph (1) to dispense such oral medication to such participant, such group health plan or a health insurance issuer (or its agent, including a pharmacy benefits manager) shall cover the medication and pay the provider or pharmacy subject to the following requirements—

“(i) such medication will be provided without imposing any requirement under the plan for prior authorization of the medication or any limitation on coverage that is more restrictive than the require-

1 ments or limitations that apply to oral
2 medications received from participating
3 providers and pharmacies with respect to
4 such plan;

5 “(ii) the cost-sharing requirement (ex-
6 pressed as a copayment amount or coinsur-
7 ance rate) is not greater than the require-
8 ment that would apply if such services
9 were provided by a participating provider
10 or a participating pharmacy;

11 “(iii) such cost-sharing requirement is
12 calculated as if the total amount that
13 would have been charged for such services
14 by such participating provider or partici-
15 pating pharmacy were equal to the recog-
16 nized amount (as determined by the Sec-
17 retary) for such oral medications, plan,
18 and year;

19 “(iv) the group health plan pays to
20 such provider or pharmacy, respectively,
21 the amount by which the recognized
22 amount for such services and year involved
23 exceeds the cost-sharing amount for such
24 services (as determined in accordance with
25 clauses (ii) and (iii)) and year;

1 “(v) any cost-sharing payments made
2 by the participant or beneficiary with re-
3 spect to such oral medication so furnished
4 shall be counted toward any in-network de-
5 ductible or out-of-pocket maximums ap-
6 plied under the plan (and such in-network
7 deductible and out-of-pocket maximums
8 shall be applied) in the same manner as if
9 such cost-sharing payments were made
10 with respect to oral medication furnished
11 by a participating provider or a partici-
12 pating pharmacy; and

13 “(vi) such medication will be provided
14 without regard to any other term or condi-
15 tion of such coverage (other than exclusion
16 or coordination of benefits, or an affiliation
17 or waiting period, permitted under section
18 2704 of this Act, including as incorporated
19 pursuant to section 715 of the Employee
20 Retirement Income Security Act of 1974
21 and section 9815 of this Act, and other
22 than applicable cost-sharing).

23 “(C) PROVIDER OR PHARMACY DE-
24 SCRIBED.—A provider or pharmacy described in
25 this subparagraph, with respect to a partici-

1 pant, beneficiary, or enrollee of a group health
2 plan or group or individual health insurance
3 coverage described in paragraph (1) and a pre-
4 scription for an oral medication for such partic-
5 ipant, beneficiary or enrollee, is a provider or
6 pharmacy that—

7 “(i) is licensed by the State in which
8 such provider or pharmacy is located to
9 dispense such oral medication, if such a li-
10 cense is required by the State;

11 “(ii) is either located within a reason-
12 able distance (as determined by the Sec-
13 retary) of the residence of such partici-
14 pant, beneficiary, or enrollee, or is able to
15 deliver such oral medication to such partici-
16 ipant, beneficiary, or enrollee at such resi-
17 dence; and

18 “(iii) is able to dispense (and if appli-
19 cable, deliver), such oral medication to
20 such participant, beneficiary, or enrollee
21 within 48 hours of the date on which it re-
22 ceives the prescription.

23 For purposes of this section, a provider or
24 pharmacy described in this subparagraph in-
25 cludes a physician or other health care practi-

1 tioner authorized to dispense oral medication to
2 such participant, beneficiary, or enrollee pursu-
3 ant to the law of the State in which the physi-
4 cian or other health care practitioner is located.

5 “(D) PRIOR AUTHORIZATION REQUIRE-
6 MENTS.—In the case of a group health plan or
7 a health insurance issuer offering group or indi-
8 vidual health insurance coverage that requires
9 prior authorization for an oral medication to be
10 dispensed to a participant, beneficiary, or en-
11 rollee of the plan or coverage, such plan or
12 issuer (or its agent, including a pharmacy bene-
13 fits manager) shall make a decision with respect
14 to a request for such a prior authorization by
15 not later than 72 hours after receiving such re-
16 quest. In the case that such plan or issuer (or
17 its agent, including a pharmacy benefits man-
18 ager) does not make a decision with respect to
19 a request for prior authorization for an oral
20 medication to be dispensed to a participant,
21 beneficiary, or enrollee of the plan or coverage
22 by the 72-hour deadline described in the pre-
23 vious sentence, such participant, beneficiary or
24 enrollee may select any pharmacy described in
25 subparagraph (C) to dispense such oral medica-

tion to such participant, beneficiary, or enrollee,
in accordance with the cost-sharing require-
ments described in subparagraph (B).

“(E) USE OF RELEVANT QUALITY MEAS-
URES UNDER INCENTIVE PAYMENT AND AD-
JUSTMENT SYSTEMS.—If a group health plan or
a health insurance issuer offering group or indi-
vidual health insurance coverage uses an incen-
tive payment and adjustment system (as de-
fined by the Secretary) in determining phar-
macy reimbursement payments for oral medica-
tions, such system shall only use quality meas-
ures that are relevant to the performance of
such pharmacy with respect to areas that the
pharmacy can impact based on the oral medica-
tions dispensed and managed by the pharmacy.

“(4) ORAL MEDICATION DEFINED.—In this
subsection, the term ‘oral medication’ means a drug
or biological (as defined in section 1861(t) of the So-
cial Security Act) that is used for a medically ac-
cepted indication that is dispensed as an outpatient
and taken by mouth.”.

(b) CONFORMING AMENDMENT.—Section 2719A(e)
of the Public Health Service Act (42 U.S.C. 300gg–

1 19a(e)) is amended by inserting “(other than subsection
2 (f))” after “The provisions of this section”.

3 (c) GAO REPORT AND RECOMMENDATIONS.—

4 (1) IN GENERAL.—Not later than 2 years after
5 the date of enactment of this Act, the Comptroller
6 General of the United States shall submit to the
7 Chair and Ranking Member of the Committee on
8 Health, Education, Labor, and Pensions of the Sen-
9 ate and the Chair and Ranking Member of the Com-
10 mittee on Energy and Commerce of the House of
11 Representatives a report on the effects of the imple-
12 mentation of subsection (f) of section 2719A of the
13 Public Health Service Act (as added by subsection
14 (a)) on the timely access of patients to oral medica-
15 tions (as defined in subsection (f)(4) of such sec-
16 tion), together with such recommendations as the
17 Comptroller General determines are appropriate.

18 (2) ITEMS INCLUDED.—The report submitted
19 under paragraph (1) shall include—

20 (A) a comparison of the amount of time
21 between the date on which a prescription is
22 written and the date on which a patient receives
23 an oral medication before and after the imple-
24 mentation of subsection (f) of section 2719A of
25 the Public Health Service Act;

1 (B) an assessment of the effects on patient
2 health outcomes, including morbidity and mor-
3 tality;

4 (C) an evaluation of costs to patients,
5 health insurance issuers, physicians, and other
6 healthcare providers; and

7 (D) a risk assessment with mitigation rec-
8 ommendations on any actual or potential fraud,
9 waste and abuse relating to the implementation
10 of such subsection.

11 (d) EFFECTIVE DATE.—The amendments made by
12 this section shall apply with respect to plan years begin-
13 ning on or after January 1, 2024.

○